This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Training and Resources

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

KEYTRUDA® (pembrolizumab) in locally advanced unresectable or metastatic oesophageal and GEJ carcinoma

 

KEYTRUDA® in combination with chemotherapy

 

PD-L1 testing and CPS interpretation in oesophageal cancer

 

Patient education and support materials

 

CPS = Combined Positive Score; GEJ = Gastroesophageal Junction

More information about KEYTRUDA® (pembrolizumab) in locally advanced unresectable or metastatic oesophageal cancer

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-02022 | Date of Preparation: April 2022